SCHEMBL29748840

SCHEMBL29748840

C[Si](C)(C)CCOCn1cc(Br)c2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 1/20 0.41
▸ NPC1 O15118 1/20 0.38
▸ ELANE P08246 1/20 0.37
▸ EGFR P00533 1/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ FLT4 P35916 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ EPHB4 P54760 1/20 0.35
▸ TEK Q02763 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ SLC22A12 Q96S37 1/20 0.34
▸ GSK3B P49841 4/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ HTR6 P50406 5/20 0.33
▸ PSMB5 P28074 2/20 0.33
▸ PSMB1 P20618 1/20 0.33
▸ PRKCB P05771 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044790 1.00 DGAT1 (0.41) DGAT1NPC1ELANEEGFRIGF1R
SCHEMBL31050029 0.85 DGAT1 (0.40) DGAT1NPC1EGFRIGF1RSRC
SCHEMBL15155202 0.83 PSMB5 (0.42) DGAT1NPC1EGFRIGF1RSRC
SCHEMBL30848403 0.82 NPC1 (0.36) DGAT1NPC1EGFRIGF1RSRC
SCHEMBL30168284 0.82 NPC1 (0.46) NPC1CNR1CNR2
SCHEMBL15546774 0.81 POLB (0.39) DGAT1NPC1EGFRIGF1RSRC
SCHEMBL29514362 0.81 ELANE (0.47) ELANE
SCHEMBL25001937 0.80 CNR1 (0.45) NPC1CNR1CNR2
SCHEMBL30848448 0.80 HTR6 (0.37) DGAT1NPC1EGFRIGF1RSRC
SCHEMBL26615066 0.80 PSMB5 (0.52) DGAT1NPC1EGFRIGF1RSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER KYORIN SEIYAKU KK (JP) 2025-10-23 — — US disclosed
WO-2024260023-A1 CYCLIC Α-HYDROXYIMIDE COMPOUND AND USE THEREOF 北京英飞智药科技有限公司 2024-12-26 — — WO disclosed
CN-119176777-A Cyclic alpha-hydroxyimide compound and application thereof 北京英飞智药科技有限公司 2024-12-24 — — CN disclosed
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
CN-109790158-B Heterocyclic compounds as JAK inhibitors, salts of the compounds and therapeutic use thereof 苏州隆博泰药业有限公司 2022-06-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326772-A1 MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER MRGPRX2, MRGPRX1, MRGPRX4 DGAT1 933/4885NPC1 54/4885ELANE 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback